Search

Jonathan E Mcdunn

age ~49

from Cary, NC

Also known as:
  • Jonathan Mcdunn
  • Jonathan Edward Mcdunn
  • Johathan Mcdunn
  • Jonathan Mcduff
  • Jmc Dunn
209 Magnolia Bloom Ct, Cary, NC 275199196503914

Jonathan Mcdunn Phones & Addresses

  • 209 Magnolia Bloom Ct, Cary, NC 27519 • 9196503914
  • 105 Wakehurst Dr, Cary, NC 27519 • 9192674854
  • 13035 Gate Dr, Poway, CA 92064
  • Wade, NC
  • 7311 Chamberlain Ave, Saint Louis, MO 63130 • 3147262457
  • San Diego, CA
  • Tampa, FL
  • Bemidji, MN
  • Dallas, TX
  • Sunnyvale, CA

Work

  • Company:
    University of north carolina
    2011
  • Position:
    Adjunct associate professor of biomedical engineering

Education

  • School / High School:
    The Scripps Research Institute
    2003
  • Specialities:
    Ph.D. in Biology

Industries

Biotechnology

Us Patents

  • Modular Platform For Targeted Therapeutic Delivery

    view source
  • US Patent:
    8143222, Mar 27, 2012
  • Filed:
    Oct 22, 2008
  • Appl. No.:
    12/255947
  • Inventors:
    Jonathan E. McDunn - University City MO,
    William G. Hawkins - Olivette MO,
    Robert H. Mach - Eureka MO,
    Richard A. Hotchkiss - Chesterfield MO,
  • Assignee:
    Washington University - Saint Louis MO
  • International Classification:
    A61K 38/02
    A61K 38/16
    C07K 2/00
    C07K 14/00
  • US Classification:
    514 189, 514 193, 514 213, 514 214, 530324, 530326, 530345, 530402
  • Abstract:
    Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kof less than about 10M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.
  • Membrane-Permeant Peptide Complexes For Treatment Of Sepsis

    view source
  • US Patent:
    20060166881, Jul 27, 2006
  • Filed:
    Nov 23, 2005
  • Appl. No.:
    11/286920
  • Inventors:
    Richard Hotchkiss - Chesterfield MO,
    David Piwnica-Worms - Ladue MO,
    Jonathan McDunn - University City MO,
  • International Classification:
    A61K 48/00
    C07K 14/475
  • US Classification:
    514012000, 514044000, 530352000
  • Abstract:
    Methods and compositions for treating sepsis using cell membrane-permeant peptide conjugate covalent compounds having target cell specificity are provided.
  • Membrane-Permeant Peptide Complexes For Treatment Of Sepsis

    view source
  • US Patent:
    20060263382, Nov 23, 2006
  • Filed:
    Mar 29, 2006
  • Appl. No.:
    11/391964
  • Inventors:
    Richard Hotchkiss - Chesterfield MO,
    David Piwnica-Worms - Ladue MO,
    Jonathan McDunn - University City MO,
  • International Classification:
    A61K 39/00
  • US Classification:
    424185100
  • Abstract:
    Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
  • Methods And Compositions For Treatment Of Sepsis

    view source
  • US Patent:
    20090012025, Jan 8, 2009
  • Filed:
    Feb 11, 2008
  • Appl. No.:
    12/029412
  • Inventors:
    Richard Hotchkiss - Chesterfield MO,
    Jonathan McDunn - University City MO,
    David Piwnica-Worms - St. Louis MO,
    Steven Schwulst - St. Louis MO,
  • International Classification:
    A61K 31/7105
    A61P 31/04
  • US Classification:
    514 44
  • Abstract:
    Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol).
  • Membrane-Permeant Peptide Complexes For Treatment Of Sepsis

    view source
  • US Patent:
    20100121031, May 13, 2010
  • Filed:
    Nov 12, 2009
  • Appl. No.:
    12/617561
  • Inventors:
    Richard Hotchkiss - Chesterfield MO,
    David Piwnica-Worms - Ladue MO,
    Jonathan McDunn - University City MO,
  • Assignee:
    WASHINGTON UNIVERSITY - St. Louis MO
  • International Classification:
    C07K 14/435
  • US Classification:
    530350
  • Abstract:
    Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided.
  • Biomarkers For Prostate Cancer And Methods Using The Same

    view source
  • US Patent:
    20130217647, Aug 22, 2013
  • Filed:
    Jul 27, 2011
  • Appl. No.:
    13/812183
  • Inventors:
    Jeffrey R. Shuster - Chapel Hill NC,
    Matthew W. Mitchell - Durham NC,
    Jonathan E. McDunn - Cary NC,
    Bruce Neri - Cary NC,
  • Assignee:
    METABOLON, INC. - Durham NC
  • International Classification:
    G01N 33/574
    A61K 31/7072
    A61K 31/685
  • US Classification:
    514 51, 436501, 435 792, 435 71, 514114
  • Abstract:
    Biomarkers (and suites of biomarkers) relating to prostate cancer are provided, as well as methods for using such biomarkers (ans suites thereof), including early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy.

Resumes

Jonathan Mcdunn Photo 1

Jonathan Mcdunn Cary, NC

view source
Work:
University of North Carolina

2011 to 2000
Adjunct Associate Professor of Biomedical Engineering
Metabolon, Inc

2011 to 2000
Associate Director, Diagnostic Development Project Management
Metabolon, Inc.
Durham, NC
2009 to 2010
Senior Study Director
Washington University School of Medicine
St. Louis, MO
2006 to 2009
Research Assistant Professor of Anesthesiology
Washington University Office of Technology Management

2003 to 2006
Postdoctoral Research Fellow
Incyte Genomics
Palo Alto, CA
1996 to 1999
Senior Research Associate
Combion, Inc
Pasadena, CA
1996 to 1996
Research Scientist
Education:
The Scripps Research Institute
2003
Ph.D. in Biology
California Institute of Technology
1996
B.S. in Chemistry
Jonathan Mcdunn Photo 2

Jonathan Mcdunn

view source
Location:
Raleigh-Durham, North Carolina Area
Industry:
Biotechnology

Get Report for Jonathan E Mcdunn from Cary, NC, age ~49
Control profile